D. A. Wagner
6 Papers
7 Citations
D. A. Wagner is an academic researcher. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study
Marja Puurunen,Jerry Vockley,Shawn L. Searle,Stephanie Sacharow,John A. Phillips,William S. Denney,Benjamin D. Goodlett,D. A. Wagner,L A Blankstein,Mary Castillo,Mark R. Charbonneau,Vincent M. Isabella,V Sethuraman,Richard J. Riese,Caroline B. Kurtz,Aoife M. Brennan +15 more
TL;DR: Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study is corrected.
309 Quantitative tests (QLFTS) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of cirrhosis, splenomegally, and varices
Gregory T. Everson,Marcelo Kugelmas,Jennifer DeSantos,Shannon Lauriski,Mitchell L. Shiffman,Richard K. Sterling,Hofmann Charlotte,Timothy R. Morgan,John C. Hoefs,Nora Milne,William Rietkerk,D. A. Wagner,Elizabeth C. Wright +12 more
7
#4328 chk-336, a first-in-class orally administered ldh inhibitor: safety, pk and target engagement in a first-in-human phase 1 healthy volunteer study
Vincent Tong,Brian Schwartz,John Knight,Sonia Fargue,D. A. Wagner,Hetal S. Kocinsky,Andrew King +6 more
TL;DR: In this paper , a first-in-human (FIH) study was conducted to evaluate the safety and pharmacokinetics of CHK-336 following single and repeat doses in healthy volunteers.
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
Gregory T. Everson,Mitchell L. Shiffman,John C. Hoefs,Timothy R. Morgan,Richard K. Sterling,D. A. Wagner,J. L. Desanto,Teresa M. Curto,Elizabeth C. Wright +8 more
TL;DR: Backgroud The impact of virologic response on hepatic function has not been previously defined and is likely to have an important impact on liver function.
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial
Gregory T. Everson,Mitchell L. Shiffman,John C. Hoefs,Timothy R. Morgan,Richard K. Sterling,D. A. Wagner,Shannon Lauriski,Teresa M. Curto,Anne M. Stoddard,Elizabeth C. Wright +9 more
TL;DR: QLFTs independently predicted outcome in models with Ishak fibrosis score, platelet count, and standard laboratory tests and could enhance the noninvasive monitoring, counseling, and management of patients with chronic HCV.